Welcome to our dedicated page for Global X SuperDividend® REIT ETF SEC filings (Ticker: SRET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Global X SuperDividend® REIT ETF's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Global X SuperDividend® REIT ETF's regulatory disclosures and financial reporting.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.
Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.
Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.
Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.
Global X Funds – Global X Russell 2000 ETF filed its monthly Form N-PORT for the period ended 30 Apr 2025. The Series reports $1.416 billion in total assets against just $0.107 million in liabilities, leaving net assets of $1.415 billion. No borrowings, preferred stock or off-balance-sheet leverage were disclosed, indicating a conservative balance sheet.
The fund posted three consecutive negative monthly total returns: -2.31%, -6.81% and -5.36%. No realized or unrealized gains/losses from derivatives were reported, underscoring a pure-equity exposure.
Securities-lending activity totalled $26.1 million, diversified across eight counterparties; the largest exposures were to UBS AG London Branch ($7.13 m) and Morgan Stanley & Co. LLC ($6.61 m). Non-cash collateral was indicated but not detailed.
Overall, the filing shows a high asset base, minimal leverage and recent performance headwinds, with no material credit or liquidity risks disclosed.
Global X Funds – Global X E-commerce ETF (Series ID S000062674) filed its Form NPORT-P for the month ended 30 April 2025.
The filing shows total assets of $66.03 million against liabilities of $0.04 million, resulting in net assets of $65.99 million. Cash and cash equivalents not otherwise classified equal $79.6 thousand, and the fund reports no debt borrowings or preferred shares, indicating a virtually un-levered balance sheet.
Performance was soft: the three most recent monthly total returns were -1.31 %, -4.60 % and -1.76 %, respectively. The fund reports no derivative exposure during the period, so market returns appear driven by underlying equity holdings.
Securities lending activity is modest relative to AUM, with roughly $3.2 million in securities on loan, the largest borrower being Morgan Stanley & Co. LLC at $1.54 million. The filing confirms that some counterparties may post non-cash collateral, but details are not provided.
Because this Form NPORT-P is marked as LIVE and not final, investors can expect continued monthly disclosures through at least the next fiscal year-end (31 Oct 2025).
FAQ
What is the current stock price of Global X SuperDividend® REIT ETF (SRET)?
